Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy

• Status: Completed
• Trial end date: 2008-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of the study is to evaluate the efficacy and the safety of pegfilgrastim versus filgrastim, administered after high-dose chemotherapy and peripheral stem cell reinfusion.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Armando Santoro, MD
• Treatments: Lenograstim

Criteria

Inclusion Criteria:

• Patients with hematological neoplasms or solid tumors candidable to high-dose chemotherapy with autologous peripheral stem cell reinfusion

• Adequate organ function

• Written informed consent.

Exclusion Criteria:

• Use of other experimental drugs

• Active infection